烯石電車新材料(06128.HK)向M3 Capital配發合共11.92萬股換股股份
格隆匯9月29日丨烯石電車新材料(06128.HK)公佈,於2022年9月27日,公司收到M3 Capital(作為票據持有人)有關按初步換股價每股普通股0.65港元行使本金額為10,000美元的可換股票據所附帶的換股權的轉換通知。因應此轉換,公司於2022年9月29日向M3 Capital配發及發行合共119,230股換股股份。該等換股股份彼此之間及與所有其他現有已發行普通股在各方面均享有同等權益。該等119,230股換股股份相當於轉換前公司已發行普通股總數約0.02%及於轉換後經配發及發行119,230股換股股份擴大的公司已發行普通股總數約0.02%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.